Alpelisib (GMP)

Overview

Alpelisib GMP is Alpelisib ( HY-15244 ) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα -selective inhibitor that blocks the conversion of PIP2 to PIP3 , thereby inhibiting pathways including PI3K/AKT/mTOR , MAPK/ERK , Notch and JAK-STAT . Alpelisib also induces apoptosis , G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin ( HY-13442 ) and exerts a synergistic effect with Paclitaxel ( HY-B0015 ), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer , gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.

Application

Products | Products > GMP Small Molecules | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-15244G
• CAS No.: 1217486-61-7
• Molecular Formula: C19H22F3N5O2S
• Molecular Weight: 441.47
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source